FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used to treat or prevent Hodgkin's lymphoma. To do this, a composition containing an inhibitor of PD-1 activity or PD-1 expression is administered.
EFFECT: invention makes it possible to increase the effectiveness of the treatment or prevention of Hodgkin's lymphoma by enhancing the specific immune response.
16 cl, 1 tbl, 14 ex, 30 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TREATING PERSISTENT INFECTIONS | 2006 |
|
RU2596491C2 |
| METHOD AND COMPOSITIONS FOR TREATMENT OF PERSISTING INFECTIONS | 2006 |
|
RU2434641C2 |
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2540490C2 |
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2478400C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| ANTIBODIES TO PD-L1 AND THEIR APPLICATION FOR T-CELLS FUNCTION STRENGTHENING | 2009 |
|
RU2636023C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| COMBINED DRUGS FOR TREATMENT OF CANCER OR INFECTION | 2016 |
|
RU2777945C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
